TB vaccination: why, when, how and what?

S. Kaufmann (Berlin, Germany)

Source: International Congress 2014 – PG20 Global evaluation of tuberculosis from children to adults
Session: PG20 Global evaluation of tuberculosis from children to adults
Session type: Postgraduate Course
Number: 50
Disease area: Paediatric lung diseases, Respiratory infections

WebcastMultimedia filesSlide presentationPDF journal article, handout or slides

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
S. Kaufmann (Berlin, Germany). TB vaccination: why, when, how and what?. International Congress 2014 – PG20 Global evaluation of tuberculosis from children to adults

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Pneumococcal vaccine: when, what, how and to whom
Source: International Congress 2014 – MS06 What's new in pneumococcal vaccination?
Year: 2014


Long-term oral antibiotic treatment: why, what, when and to whom?
Source: Eur Respir Monogr 2017; 75: 185-205
Year: 2017


What do they know about TB?
Source: Eur Respir J 2002; 20: Suppl. 38, 163s
Year: 2002

Chest drain insertion in a teaching hospital: Who, what, why, where, when and how?
Source: Annual Congress 2010 - Novel approach in diagnosis and treatment of pleural effusions
Year: 2010

Latent TB: what's next?
Source: Annual Congress 2007 - Latent tuberculosis: what's next?
Year: 2007

Treatment for NTM: when, how... and what next?
Source: ERS Course 2015
Year: 2015

A time to live, a time to die, but who decides when, and why? Advance decision making for two patients with ALS
Source: Annual Congress 2009 - Difficult ethical decisions Grand Round - An interactive session
Year: 2009


Clustering in asthma: why, how and for how long?
Source: Eur Respir J 2013; 41: 1247-1248
Year: 2013


TB patients are coming back to hospital – why?
Source: Annual Congress 2008 - Clinical epidemiology of tuberculosis III
Year: 2008

TB following targeted and biological therapy: can we predict it?
Source: Virtual Congress 2020 – Tuberculosis and comorbidities
Year: 2020


The burden of TB–HIV in the EU: how much do we know? A survey of surveillance practices and results
Source: Eur Respir J 2011; 38: 1374-1381
Year: 2011



Asthma control test: how? And where?
Source: Annual Congress 2008 - Asthma control or asthma severity
Year: 2008


Tuberculosis screening in immigrants - is it worth doing?
Source: Annual Congress 2005 - Epidemiology and control of tuberculosis and LTBI
Year: 2005


TB in children: still a real problem?
Source: School Course 2012 - TB and M/XDR-TB: from clinical management to control and elimination
Year: 2012


TB and COVID-19 – a dangerous new combination?
Source: ERS webinar 2021: TB and COVID-19 – a dangerous new combination?
Year: 2021


What we know and what we do not know about cannabis health effects: a concern for lung health?
Source: Virtual Congress 2020 – The changing and challenging landscape of the global tobacco epidemic: from vaping to cannabis?
Year: 2020

Immunotherapy: when, who and which drug?
Source: International Congress 2018 – New drugs, strategies and research designs for advanced non-small cell lung cancer
Year: 2018


Positional therapy: who, when and how?
Source: Sleep and Breathing Conference 2021
Year: 2021


"Don’t get me wrong, I think case finding is okay" Exploring healthcare professionals’ perspectives on target case-finding for COPD
Source: International Congress 2016 – Screening, diagnosis, assessment, and treatment of COPD in primary care
Year: 2016